Results 1 to 10 of about 926 (69)

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel

Experimental Hematology & Oncology, 2022
Background There are no head-to-head clinical studies comparing chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed or refractory aggressive large B-cell lymphomas. Naive, indirect comparisons may be inappropriate, as the study
Guillaume Cartron, Christopher P. Fox, Fei Fei Liu, Ana Kostic, Jens Hasskarl, Daniel Li, Ashley Bonner, Yixie Zhang, David G. Maloney, John Kuruvilla   +9 more
doaj   +1 more source

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma

Journal of Hematology & Oncology, 2021
Background In the absence of randomized studies directly comparing chimeric antigen receptor T cell therapies, this study used matching-adjusted indirect comparisons (MAIC) to evaluate the comparative efficacy and safety of lisocabtagene maraleucel (liso-
David G. Maloney, John Kuruvilla, Fei Fei Liu, Ana Kostic, Yeonhee Kim, Ashley Bonner, Yixie Zhang, Christopher P. Fox, Guillaume Cartron   +8 more
doaj   +1 more source

Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison

Rheumatology and Therapy, 2023
Introduction The efficacy of sarilumab and upadacitinib, in combination with disease-modifying antirheumatic drugs (DMARDs), was demonstrated in phase 3 clinical trials of patients with rheumatoid arthritis (RA) refractive to previous biologic DMARDs. In
Thomas Huizinga, Ernest Choy, Amy Praestgaard, Hubert van Hoogstraten, Patrick R. LaFontaine, Patricia Guyot, Daniel Aletaha, Ulf Müller-Ladner, Yoshiya Tanaka, Jeffrey R. Curtis, Roy Fleischmann   +10 more
doaj   +1 more source

QDOT MICRO versus THERMOCOOL SMARTTOUCH and THERMOCOOL SMARTTOUCH Surround Flow in radiofrequency ablation of paroxysmal atrial fibrillation

Journal of Comparative Effectiveness Research, 2023
Aim: The objective of this study was to indirectly compare QDOT MICRO™ (QDOT), Thermocool R  SmartTouch™ (ST) and Thermocool R  SmartTouch R  Surround Flow (STSF) to treat paroxysmal atrial fibrillation.
Jose Osorio, Sonia Maccioni, Reecha Sharma, Leena Patel, Paul Spin, Andrea Natale   +5 more
doaj   +1 more source

Two-stage matching-adjusted indirect comparison

BMC Medical Research Methodology, 2022
Background Anchored covariate-adjusted indirect comparisons inform reimbursement decisions where there are no head-to-head trials between the treatments of interest, there is a common comparator arm shared by the studies, and there are patient-level data
Antonio Remiro-Azócar
doaj   +1 more source

How compare biologics applied for rheumatic disorders?

Rheumatology, 2014
Management of patients with rheumatoid arthritis remains a major clinical problem but introduction of biologics significantly improved therapeutical strategy. Biologics reduce inflammation and its sequelae, including structural joint damage.
Eugeniusz J. Kucharz
doaj   +1 more source

Indirect comparison of efficacy between different antibiotic prophylaxis against the intracranial infection after craniotomy

Antimicrobial Resistance and Infection Control, 2020
Background Many studies had shown that prophylactic use of antibiotics could significantly reduce the intracranial infection (ICI) rate of craniotomy. However, there has been no comparison of these antibiotics.
Yulong Cao, Bin Wang, Jiao Shan, Zhizhong Gong, Jiqiu Kuang, Yan Gao   +5 more
doaj   +1 more source

Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison

Dermatology and Therapy
Introduction Dupilumab and lebrikizumab have demonstrated efficacy in atopic dermatitis (AD) clinical trials; however, no direct comparisons exist. Methods Efficacy outcome achievement (dupilumab and lebrikizumab with topical corticosteroids [TCS]) at 16 
Sonja Ständer, Andreas Pinter, Firas G. Hougeir, Patricia Guyot, Yingxin Xu, Amy H. Praestgaard, Nick Freemantle, Ana B. Rossi, Gaëlle Bégo-Le-Bagousse, Zhixiao Wang, Kerry Noonan, Mike Bastian   +11 more
doaj   +1 more source

Can We Trust PAICs in Rare Diseases? Methodological Challenges and Limitations

Journal of Market Access & Health Policy
Population-adjusted indirect comparisons (PAICs), including Matching-Adjusted Indirect Comparison and Simulated Treatment Comparison, are increasingly used to inform health technology assessments.
Mikolaj Parkitny, Samuel Aballéa, Piotr Wojciechowski, Mondher Toumi   +3 more
doaj   +1 more source

Evidence Synthesis via Indirect Treatment Comparisons in the European Framework of Joint Clinical Assessment

Epidemiologia
The application of the Health Technology Assessment Regulation (HTAR) gives way to joint European work, such as the Joint Clinical Assessment (JCA).
Alberto de la Cuadra-Grande, María Arruñada, Alejandro García-Solís, Ana Rossignoli-Montero, Miguel Ángel Casado   +4 more
doaj   +1 more source